Login
Publications |
nEuroPro Publications
- Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study. Myöhänen TT, Venäläinen JI, Garcia-Horsman JA, Männistö PT. Neuroscience. 2008 153(4):1177-89. http://www.ncbi.nlm.nih.gov/pubmed/18455882 - Characterization of membrane-bound prolyl endopeptidase from brain. Tenorio-Laranga J, Venäläinen JI, Männistö PT, García-Horsman JA. FEBS J. 2008 275(17):4415-27. http://www.ncbi.nlm.nih.gov/pubmed/18657187 - Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Moreno-Baylach MJ, Felipo V, Männistö PT, García-Horsman JA. Neuroscience. 2008 156(3):580-5. http://www.ncbi.nlm.nih.gov/pubmed/18718510 - Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Myöhänen TT, Venäläinen JI, García-Horsman JA, Piltonen M, Männistö PT. Histochem Cell Biol. 2008 130(5):993-1003. http://www.ncbi.nlm.nih.gov/pubmed/18618130 - Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain. Myöhänen TT, Kääriäinen TM, Jalkanen AJ, Piltonen M, Männistö PT. Neurosci Lett. 2009 450(2):201-5. http://www.ncbi.nlm.nih.gov/pubmed/19041368 - Bioactive peptides, networks and systems biology. Boonen K, Creemers JW, Schoofs L. Bioessays. 2009 31(3):300-14. http://www.ncbi.nlm.nih.gov/pubmed/19260025 - Characterization of a novel acylaminoacyl peptidase with hexameric structure and endopeptidase activity. Szeltner Z, Kiss AL, Domokos K, Harmat V, Náray-Szabó G, Polgár L. Biochim Biophys Acta. 2009 1794(8):1204-10. http://www.ncbi.nlm.nih.gov/pubmed/19303951 - Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. Myöhänen TT, García-Horsman JA, Tenorio-Laranga J, Männistö PT. J Histochem Cytochem. 2009 57(9):831-48. http://www.ncbi.nlm.nih.gov/pubmed/19687473 - Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomics analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. Tenorio-Laranga J, Valero ML, Männistö PT, Sánchez del Pino M, García-Horsman JA. Anal Biochem. 2009 393(1):80-7. http://www.ncbi.nlm.nih.gov/pubmed/19539595 - Prolyl oligopeptidase activity is inhibited in blood-plasma of relapsing-remitting multiple sclerosis patients. Tenorio-Laranga J, Burgal M, Coret-Ferrer F, Casanova-Estruch B, García-Horsman JA. Journal of Neuroinflammation. 2010 7:23. http://www.ncbi.nlm.nih.gov/pubmed/20370893 - Neurons associated with aggrecan-based perineuronal nets are protected against tau pathology in subcortical regions in Alzheimer’s disease. Morawski M, Brückner G, Jäger C, Seeger G, Arendt, T. Neuroscience. 2010 169(3):1347-63. http://www.ncbi.nlm.nih.gov/pubmed/20497908 - Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Aβ pathology in Alzheimer’s disease. Morawski M, Hartlage-Rübsamen M, Jäger C, Waniek A, Schilling S, Schwab C, McGeer P, Arendt T, Demuth HU, Roßner S. Acta Neuropathol. 2010 120(2):195-207. http://www.ncbi.nlm.nih.gov/pubmed/20383514 - GAP43 shows partial co-localisation but no strong physical interaction with prolyl oligopeptidase. Szeltner Z, Morawski M, Juhasz T, Szamosi I, Liliom K, Csizmok V, Tolgyesi F, Polgar L. Biochimica et Biophysica Acta, Proteins and Proteomics 2010 1804(12):2162-76. http://www.ncbi.nlm.nih.gov/pubmed/20869470 - Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide. Racys DT, Rea D, Fülöp V, Wills M. Bioorg. Med. Chem. 2010 18(13):4775-4782. http://www.ncbi.nlm.nih.gov/pubmed/20627594 - Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain. Hannula MJ, Männistö PT, Myöhänen TT. Dev Neurosci. 2011 33(1):38-47. http://www.ncbi.nlm.nih.gov/pubmed/21160163 - Prolyl Oligopeptidase Structure and Dynamics. Rea D, Fülöp V. CNS Neurol Disord Drug Targets. 2011 10(3):306-10. http://www.ncbi.nlm.nih.gov/pubmed/21222626 - Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain. Peltonen I, Myöhänen TT, Männistö P. CNS Neurol Disord Drug Targets. 2011 10(3):311-8. http://www.ncbi.nlm.nih.gov/pubmed/21222629 - Interaction of Prolyl Oligopeptidase with α-Synuclein. Lambeir AM. CNS Neurol Disord Drug Targets. 2011 10(3):349-54. http://www.ncbi.nlm.nih.gov/pubmed/21222624 - Structure and Function Relationship in Prolyl Oligopeptidase. Van Elzen R, Lambeir AM. CNS Neurol Disord Drug Targets. 2011 10(3):297-305. http://www.ncbi.nlm.nih.gov/pubmed/21222621 - Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides. Tenorio-Laranga J, Männistö PT, García-Horsman JA. CNS Neurol Disord Drug Targets. 2011 10(3):319-26. http://www.ncbi.nlm.nih.gov/pubmed/21222622 - Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research. Penttinen A, Tenorio-Laranga J, Siikanen A, Morawski M, Rossner S, García-Horsman JA. CNS & Neurol Disord Drug Targets, 2011 10(3):340-8. http://www.ncbi.nlm.nih.gov/pubmed/21222623 - PREPL, a prolyl endopeptidase-like enzyme by name only? - lessons from patients. Boonen K, Régal L, Jaeken J, Creemers JW. CNS Neurol Disord Drug Targets. 2011 10(3):355-60. http://www.ncbi.nlm.nih.gov/pubmed/21222627 - Role of prolyl oligopeptidase in intracellular transport and protein secretion. Morawski M, Schulz I, Zeitschel U, Blosa M, Seeger G, Rossner S. CNS Neurol Disord Drug Targets. 2011 10(3):327-32. http://www.ncbi.nlm.nih.gov/pubmed/21222628 - Structure and catalysis of acylaminoacyl peptidase: closed and open subunits of a dimer oligopeptidase. Harmat V, Domokos K, Menyhárd DK, Palló A, Szeltner Z, Szamosi I, Beke-Somfai T, Náray-Szabó G, Polgár L. J Biol Chem. 2011 286(3):1987-98. http://www.ncbi.nlm.nih.gov/pubmed/21084296 - Translational research on prolyl oligopeptidase inhibitors: the long road ahead. Lambeir AM. Expert Opin Ther Pat. 2011 21(7):977-81. http://www.ncbi.nlm.nih.gov/pubmed/21679099 - Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum. Jalkanen A, Savolainen K, Forsberg M. Neurosci Lett. 2011 502(2):107-11. http://www.ncbi.nlm.nih.gov/pubmed/21820035 - Heteroarylketones inhibit astroglial interleukin-6 expression via a STAT3/NF-kappaB signaling pathway. Schulz I, Engel C, Niestroj AJ, Zeitschel U, Menge K, Kehlen A, Meyer A, Rossner S, Demuth HU. J. Neuroinflamm., 2011, 8:86. http://www.ncbi.nlm.nih.gov/pubmed/21801384 - Prolyl oligopeptidase is involved in cellular signalling in human neuroblastoma SH-SY5Y cells. Moreno-Baylach MJ, Puttonen KA, Tenorio-Laranga J, Venäläinen JI, Storvik M, Forsberg MM, Garcia-Horsman JA. Neurosignals. 2011 19(2):97-109. http://www.ncbi.nlm.nih.gov/pubmed/21487212 - Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat. Jalkanen A, Hakkarainen J, Lehtonen M, Venäläinen T, Kääriäinen T, Jarho E, Suhonen M, Forsberg M. Basic & Clinical Pharmacology & Toxicology. 2011 109(6):443-51. |